BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26875581)

  • 1. [Analysis of clinical manifestations and risk factors of mortality in Acinetobacter baumannii bloodstream infection].
    Zhang Y; Zhou H; Cai H; Yang Q; Shen Q; Shen Y; Zhou J
    Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):121-6. PubMed ID: 26875581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of risk factors on prognosis of Acinetobacter baumannii bloodstream infection].
    Qiao L; Zhang JS; Mei YN; Zhang HZ; Su CL
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):471-4. PubMed ID: 24021042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection.
    Lee YT; Kuo SC; Yang SP; Lin YT; Tseng FC; Chen TL; Fung CP
    Clin Infect Dis; 2012 Jul; 55(2):209-15. PubMed ID: 22495546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
    Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome.
    Brotfain E; Borer A; Koyfman L; Saidel-Odes L; Frenkel A; Gruenbaum SE; Rosenzweig V; Zlotnik A; Klein M
    J Intensive Care Med; 2017 Oct; 32(9):528-534. PubMed ID: 26902255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China.
    Yu K; Zeng W; Xu Y; Liao W; Xu W; Zhou T; Cao J; Chen L
    Antimicrob Resist Infect Control; 2021 Jan; 10(1):16. PubMed ID: 33461617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study.
    Chen CT; Wang YC; Kuo SC; Shih FH; Chen TL; How CK; Yang YS; Lee YT
    J Microbiol Immunol Infect; 2018 Oct; 51(5):629-635. PubMed ID: 28701266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
    Wang Q; Huang M; Zhou S
    J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality risk factors of Acinetobacter baumannii bacteraemia.
    Choi JY; Park YS; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YA; Song YG; Yong D; Lee K; Kim JM
    Intern Med J; 2005 Oct; 35(10):599-603. PubMed ID: 16207259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of unforeseen intractable severe bacteremia due to Acinetobacter baumannii--an efficacy of sulbactam--.
    Takahashi N; Shimada T; Tanabe K; Sato M; Kitamura J; Sato H; Yoshitomi H; Ishibashi Y; Sakane T
    Jpn J Infect Dis; 2009 Nov; 62(6):461-3. PubMed ID: 19934540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology.
    Wang X; Zhang L; Sun A; Yang X; Sang W; Jiang Y; Cheng J; Wang J; Zhou M; Chen B; Ouyang J
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1073-1081. PubMed ID: 28101785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
    Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
    Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores.
    Chen SJ; Chao TF; Chiang MC; Kuo SC; Chen LY; Yin T; Chen TL; Fung CP
    Intern Med; 2011; 50(8):871-7. PubMed ID: 21498935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: A retrospective study from a Chinese hospital.
    Zhou H; Yao Y; Zhu B; Ren D; Yang Q; Fu Y; Yu Y; Zhou J
    Medicine (Baltimore); 2019 Mar; 98(13):e14937. PubMed ID: 30921191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
    Anunnatsiri S; Tonsawan P
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections].
    Shi Y; Xu YC; Liu Y; Du W; Rui X; Wang Y
    Zhonghua Yi Xue Za Zhi; 2012 Oct; 92(40):2847-50. PubMed ID: 23290215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia.
    Kuo SC; Lee YT; Yang SP; Chiang MC; Lin YT; Tseng FC; Chen TL; Fung CP
    Clin Microbiol Infect; 2013 Jul; 19(7):634-9. PubMed ID: 22776466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Vandepitte WP; Berge J; Andersson R
    J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.